Table 2.
Clinical characteristics of sICAS patients according to the initial stroke severity and short-term prognosis.
| Variables | Mild (n = 698) | Severe (n = 201) | P-value | Favorable (n =521) | Unfavorable (n = 378) | P-value |
|---|---|---|---|---|---|---|
| (NIHSS ≤ 8) | (NIHSS >8) | (mRS 0–2) | (mRS 3–6) | |||
| Age (years) | 61 (52–68) | 63 (54–69) | 0.080 | 60 (52–68) | 63 (53–69) | 0.015 |
| Sex, male, N (%) | 464 (66.5%) | 114 (56.7%) | 0.011 | 360 (69.1%) | 218 (57.7%) | <0.001 |
| Hypertension, N (%) | 542 (77.7%) | 157 (78.1%) | 0.890 | 399 (76.6%) | 300 (79.4%) | 0.322 |
| Diabetes, N (%) | 237 (34.0%) | 73 (36.3%) | 0.534 | 166 (31.9%) | 144 (38.1%) | 0.052 |
| Dyslipidemia, N (%) | 313 (44.8%) | 99 (49.3%) | 0.269 | 231 (44.3%) | 181 (47.9%) | 0.292 |
| CAD, N (%) | 96 (13.8%) | 34 (16.9%) | 0.261 | 60 (11.5%) | 70 (18.5%) | 0.003 |
| Smoking, N (%) | 304 (43.6%) | 86 (42.8%) | 0.847 | 241 (46.3%) | 149 (39.4%) | 0.041 |
| Drinking, N (%) | 228 (32.7%) | 74 (36.8%) | 0.272 | 189 (36.3%) | 113 (29.9%) | 0.046 |
| IVT, N (%) | 15 (2.1%) | 6 (3.0%) | 0.439 | 10 (1.9%) | 11 (2.9%) | 0.375 |
| EVT, N (%) | 22 (3.2%) | 3 (1.5%) | 0.328 | 17 (3.3%) | 8 (2.1%) | 0.412 |
| Dual antiplatelets, N (%) | 349 (50.0%) | 84 (41.8%) | 0.045 | 281 (53.9%) | 152 (40.2%) | <0.001 |
| Severity of stenosis, N(%) | <0.001 | <0.001 | ||||
| Mild | 128 (18.3%) | 20 (10.0%) | 98 (18.8%) | 50 (13.2%) | ||
| Moderate | 170 (24.4%) | 42 (20.9%) | 118 (22.6%) | 94 (24.9%) | ||
| Severe | 154 (22.1%) | 34 (16.9%) | 127 (24.4%) | 61 (16.1%) | ||
| Occlusion | 246 (35.2%) | 105 (52.2%) | 178 (34.2%) | 173 (45.8%) | ||
| Number of stenosis, N(%) | 0.821 | 0.610 | ||||
| 1 | 191 (27.4%) | 51 (25.4%) | 137 (26.3%) | 105 (27.8%) | ||
| 2 | 148 (21.2%) | 42 (20.9%) | 116 (22.3%) | 74 (19.6%) | ||
| ≥ 3 | 359 (51.4%) | 108 (53.7%) | 268 (51.4%) | 199 (52.6%) | ||
| HT, N (%) | 37 (5.3%) | 15 (7.5%) | 0.235 | 26 (5.0%) | 26 (6.9%) | 0.249 |
| ECASS II classification, N(%) | 0.320 | 0.161 | ||||
| HI1, N (%) | 9 (1.3%) | 3 (1.5%) | 6 (1.2%) | 6 (1.6%) | ||
| HI2, N (%) | 15 (2.1%) | 4 (2.0%) | 13 (2.5%) | 6 (1.6%) | ||
| PH1, N (%) | 5 (0.7%) | 5 (2.5%) | 3 (0.6%) | 7 (1.9%) | ||
| PH2, N (%) | 8 (1.1%) | 3 (1.5%) | 4 (0.8%) | 7 (1.9%) | ||
| Moderate–severe CED, N (%) | 43 (6.2%) | 44 (21.9%) | <0.001 | 39 (7.5%) | 48 (12.7%) | 0.012 |
| SBP (mmHg) | 144 (132–158) | 147 (134–160) | 0.208 | 143 (132–156) | 146 (134–160) | 0.102 |
| DBP (mmHg) | 84 (76–93) | 85 (76–92) | 0.861 | 84 (76–93) | 85 (76–92) | 0.986 |
| WBC (×109/L) | 6.70 (5.50–8.10) | 7.70 (6.30–9.75) | <0.001 | 6.70 (5.47–8.10) | 7.20 (5.90–8.70) | <0.001 |
| Plt (×109/L) | 205.00 (169.00–246.00) | 218.00 (171.75–259.50) | 0.06 | 204.00 (164.50–244.00) | 211.50 (176.00–256.25) | 0.021 |
| Neutrophil (×109/L) | 4.30 (3.30–5.40) | 5.30 (4.00–7.00) | <0.001 | 4.20 (3.20–5.30) | 4.80 (3.80–6.40) | <0.001 |
| Lymphocyte (×109/L) | 1.60 (1.20–2.00) | 1.40 (1.10–1.90) | 0.003 | 1.60 (1.20–2.00) | 1.50 (1.20–1.90) | 0.010 |
| NLR | 2.63 (1.93–3.64) | 3.53 (2.43–5.25) | <0.001 | 2.60 (1.88–3.54) | 3.18 (2.25–4.53) | <0.001 |
| TC (mmol/L) | 4.37 (3.54–5.16) | 4.42 (3.74–5.25) | 0.157 | 4.34 (3.54–5.14) | 4.45 (3.63–5.20) | 0.168 |
| TG (mmol/L) | 1.57 (1.18–2.11) | 1.54 (1.19–2.20) | 0.991 | 1.58 (1.18–2.11) | 1.54 (1.20–2.17) | 0.924 |
| HDL (mmol/L) | 1.00 (0.85–1.18) | 1.02 (0.89–1.23) | 0.131 | 0.99 (0.84–1.17) | 1.02 (0.88–1.24) | 0.045 |
| LDL (mmol/L) | 2.66 (2.10–3.29) | 2.75 (2.16–3.35) | 0.143 | 2.63 (2.10–3.27) | 2.76 (2.13–3.38) | 0.133 |
| FBG (mmol/L) | 5.56 (4.91–7.17) | 6.15 (5.19–7.96) | <0.001 | 5.54 (4.91–6.99) | 5.95 (5.07–7.82) | 0.002 |
| UA (μmol/L) | 315.70 (261.45–381.72) | 290.60 (230.95–365.00) | 0.002 | 318.50 (271.10–383.19) | 300.39 (234.57–370.55) | 0.003 |
| Hcy (μmol/L) | 13.45 (11.04–16.41) | 12.59 (11.11–16.51) | 0.578 | 13.43 (11.12–16.48) | 13.27 (11.01–16.36) | 0.445 |
| Fib (g/L) | 3.20 (2.74–3.89) | 3.69 (2.96–4.39) | <0.001 | 3.15 (2.71–3.86) | 3.45 (2.90–4.25) | <0.001 |
Bold values denote statistical significance at the P < 0.05 level. NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; sICAS, symptomatic intracranial atherosclerotic stenosis; CAD, coronary artery disease; IVT, intravenous thrombolysis; EVT, endovascular therapy; HT, hemorrhagic transformation; ECASS II, European Cooperative Acute Stroke Study II; HI, hemorrhagic infarction; PH, parenchymal hematoma; CED, cerebral edema; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; Plt, platelet; NLR, neutrophil-to-lymphocyte ratio; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FBG, fasting blood glucose; UA, uric acid; Hcy, homocysteine; Fib, fibrinogen.